The Monday Brief — Week of Jul 30, 2026

Galderma reported record H1 2026 net sales of $3.134 billion with 24.6% year-on-year growth at constant currency—and the company raised its full-year guidance. The driver? GLP-1 weight-loss drugs are now a documented demand accelerator: the company explicitly credited a 25% boost to aesthetics sales to the GLP-1 trend, as patients on these medications seek treatments for facial volume loss and skin laxity.

• Record H1 sales and raised FY guidance signal confidence in sustained demand
• GLP-1 tailwinds are now quantified and expected to persist
• Nemluvio strength and portfolio breadth supporting growth

For independent practices, this means the GLP-1 patient is no longer a niche—it's a structural market shift. Practices should be prepared to discuss facial rejuvenation, skin tightening, and volume restoration as part of the post-weight-loss journey.

Alma Lasers launched the Harmony platform in India this week, joining a broader push into emerging markets. Meanwhile, Daewoong's Nabota entered Kuwait, completing its sweep of seven Middle East markets—signaling aggressive geographic expansion by non-Galderma players. Galderma itself launched Alastin across key Asia-Pacific markets, doubling down on regional presence.

• Platform consolidation (Alma Harmony) aims to simplify practice workflows
• Nabota's Middle East expansion signals emerging-market appetite for alternatives
• Galderma's Alastin push in APAC reflects confidence in regional demand

Practices in growth markets should monitor these launches for competitive positioning and potential supply/pricing shifts. Established players are betting on emerging markets; practices in those regions may see margin pressure or new partnership opportunities.

Media coverage of 'Ozempic face' facials and a Botox boom tied to GLP-1 use is now mainstream. Bridal shops in Iowa are adapting to brides on weight-loss drugs; practices are responding with targeted treatments for facial hollowing, skin texture, and dynamic wrinkles. This is a demand signal, not a fad.

• GLP-1 patients are actively seeking aesthetic solutions
• Facial volume loss and skin laxity are the primary drivers
• Bundled services (neuromodulators + fillers + skin treatments) are gaining traction

Owners should consider service bundling and patient education around the GLP-1 journey. Marketing to this cohort—and positioning your practice as a partner in post-weight-loss aesthetics—is a competitive advantage.

SkinStylus received FDA clearance for periorbital wrinkles across all skin types. SKINVIVE by JUVÉDERM continues gaining traction for neck lines. But regulatory pressure is mounting: Indiana's Public Law 136 tightens medical spa regulations, signaling a trend toward stricter state-level oversight of non-physician-led practices.

• New FDA clearances expand treatment options but don't change competitive dynamics
• State-level regulation is tightening; compliance costs may rise
• Indiana's move may signal a broader regulatory wave

Review your state's regulatory landscape now. If you operate in or near states considering stricter rules, audit your staffing, credentialing, and protocols. Regulatory compliance is becoming a competitive moat—practices that stay ahead will have fewer disruptions.

Xeomin is entering the conversation around neurotoxin resistance—a clinical phenomenon where repeat patients show diminished response to standard neuromodulators. This positions Xeomin as a potential switch option for patients who've plateaued on other toxins.

• Neurotoxin resistance is a real clinical issue gaining mainstream attention
• Xeomin's formulation (no complexing proteins) is being positioned as a solution
• Patient education around rotation or switching is becoming a practice differentiator

Owners should educate staff on resistance mechanisms and have a clear protocol for patient conversations around toxin rotation or switching. This is a retention and upsell opportunity.

Daewoong's Nabota hit 1 trillion won in cumulative sales—a symbolic and financial milestone that underscores the global botulinum toxin market's expansion beyond Allergan/Galderma. Nabota's Middle East expansion and cumulative sales growth reflect a fragmented, competitive market where alternatives are gaining share.

• Nabota's milestone signals a maturing alternative toxin market
• Geographic expansion is the growth lever for non-Galderma players
• Pricing and rebate pressure may intensify as alternatives gain share

Practices should monitor toxin pricing and rebate programs closely. Galderma's dominance is real, but alternatives are gaining traction—and your rebate terms may shift. Lock in favorable terms now if possible, and maintain relationships with multiple suppliers.

The aesthetic lasers market is projected to reach $11.1 billion by 2036, reflecting sustained demand for non-invasive and minimally invasive treatments. This growth is underpinned by aging populations, GLP-1 trends, and rising consumer spending on aesthetics.

• Laser and energy-based device market is on a strong growth trajectory
• GLP-1 and demographic trends are structural tailwinds
• Platform consolidation and geographic expansion will define competitive positioning

For practices, this is a signal to invest in laser and device capabilities if you haven't already. The market is expanding, and practices with diverse treatment modalities will capture more of the GLP-1 and post-weight-loss patient cohort.